Abstract: This invention provides compositions and methods related to the administration of red yeast rice, coenzyme Q10, and chromium, with or without inositol hexanicotinate, selenium, and mixed tocopherols to reduce or control blood cholesterol, triglycerides, low density lipoproteins, or increasing or controlling high density lipoproteins in a mammal, to reduce arterial plaque build-up, atherosclerosis, in a mammal which may be associated with cardiovascular, cerebrovascular, peripheral vascular, or intestinal vascular disorders.

Abstract: Methods and compositions are disclosed for prevention and/or treatment of diseases in which 5- and 12-lipoxygenase activity contributes to the pathological condition, by administration of 12-methyletradecanoic acids alone and in conjunction with other therapeutic compounds. Methods to inhibit lipoxygenase-mediated inflammations are disclosed.

Abstract: This invention provides compositions and methods related to the administration of red yeast rice, coenzyme Q10, and chromium, with or without inositol hexanicotinate, selenium, and mixed tocopherols to reduce or control blood cholesterol, triglycerides, low density lipoproteins, or increasing or controlling high density lipoproteins in a mammal, to reduce arterial plaque build-up, atherosclerosis, in a mammal which may be associated with cardiovascular, cerebrovascular, peripheral vascular, or intestinal vascular disorders.

Abstract: This invention provides compositions and methods related to the administration of red yeast rice, coenzyme Q10, and chromium, with or without inositol hexanicotinate, selenium, and mixed tocopherols to reduce or control blood cholesterol, triglycerides, low density lipoproteins, or increasing or controlling high density lipoproteins in a mammal, to reduce arterial plaque build-up, atherosclerosis, in a mammal which may be associated with cardiovascular, cerebrovascular, peripheral vascular, or intestinal vascular disorders.

Abstract: The present in to s directed to compounds of the formula I: (wherein R1, R2, R3, R7, R8, X, Y, Z, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.

Abstract: An agent for preventing and curing the hindrance of ischemic reperfusiton is disclosed which has as an active component thereof a chromanol glycoside represented by the following general formula: [wherein R1, R2, R3, and R4 independently denote a hydrogen atom or a lower alkyl group, R5 denotes a hydrogen atom, a lower alkyl group, or a lower acyl group, X denotes a monosaccharide residue or an oligosaccharide residue which may have a lower alkyl group or a lower acyl group substituted for the hydrogen atom of the hydroxyl group of the saccharide residue, n denotes an integer of 0-6, and m denotes an integer of 1-6]. The agent, even in a small dosage, acts safely and effectively on the affected part and allows the hindrances of ischemic reperfusion induced in heart, stomach, small intestine, liver, spleen, kidney, brain, and skin, and the hindrance induced during the transplantation of an internal organ to be prevented and cured.

Abstract: Lipid metabolic disorders, such as hyperlipidemia or hyperlipoproteinemia can be treated by administering to an afflicted individual an effective amount of 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or one of its physiologically acceptable salts. Pharmaceutical compositions containing (&agr;-lipoic acid) and methods for making such compositions also are disclosed.

Abstract: A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.

Abstract: A panax notoginsenoside composition for patients having coronary heart disease, high blood pressure, high blood fat, and high cholesterol, consists of 41% by weight of panax notoginsenoside powder extracted from panax notoginseng (Burk.) F. H. chen ex C. Chow et al, 0.5% by weight of beeswax, 58.48% by weight of peanut oil, and 0.02% by weight of BHT.

Abstract: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.

Abstract: The present invention is directed to a composition comprising a therapeutically effective amount of exogenous heparin and arginine or physiologically acceptable salts thereof which is used in the treatment and prevention of cardiovascular diseases or disorders.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include a nicotinic acid derivative combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract: An important aspect of the present invention is a method for inhibiting proliferation of a DNA virus dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus. The method involves administering prophylactically or therapeutically effective amount of a cyclin-dependent kinase inhibitor to a patient or animal.

Abstract: A daily administration of a rose-hip concentrate and fish oil is used to treat and/or alleviate the symptoms associated with joint disease such as osteoarthritis, specifically joint pain and stiffness. By administering the combination on a daily basis, a significant reduction in pain and stiffness of the joints affected by joint disease is attained which allows individuals suffering from joint disease to substantially resume daily activities.

Abstract: A method of treating or preventing vascular disease in a living organism. The method includes delivering an effective amount of a composition including a sex hormone, anti-hormone, sex-hormone agonist, steroid-hormone inhibitor/antagonist (partial or full), selective estrogen receptor modulator (SERM), or a combination thereof, to an affected area of a living organism.

Abstract: A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which consists essentially of a multiplicity of killed whole-virus strains, selected from the group consisting of: Herpes Simplex Virus 1; Herpes Simplex Virus 2; Herpes Simplex Virus 6; Human Cytomegalovirus; and Epstein-Barr Virus; in combination with a pharmaceutically acceptable inert vaccine carrier or diluent.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include a fibric acid derivative combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an ileal bile acid transport inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract: A compound which is an antagonist of platelet activating factor (PAF-antagonist) or a structurally related compound thereof not having PAF-antagonistic activity can be used for decreasing the plasma level of lipoprotein(a) and/or increasing the plasma level of high-density lipoprotein. The compound may be an azepine derivative, especially a benzo- or thienotriazolo-diazepine derivative, a diphenyl-tetrahydrofuran or diphenyldioxolane derivative or a tetrahydrofuran phospholipid analogue.

Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

Abstract: A process for obtaining the apolar extract comprises: (a) extracting the rhizomes with an organic solvent; (b) filtration and evaporation to dryness of the extract; (c) dissolution of the oleoresin obtained in hot conditions, precipitation while allowing to cool down and filtration of the solid; (d) drying and recrystallizing the solid in order to obtain a product having a purity in curcuminoids higher than 90%. Obtaining the polar extract comprises: (a′) extraction of the rhizomes with water at 50-70° C. and (b′) filtration and evaporation of the water. Application of the compositions and preparations as catchers of free radicals and antiageing agents, as well as reducing agents to reduce the plasma levels of lipid peroxides in human beings are disclosed.

Abstract: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.

Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymer characterized by a repeat unit having the formula: and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.

Abstract: Described herein are novel, therapeutic pharmaceutical and nutraceutical compositions useful for treating stenotic vascular diseases and disorders, such as atherosclerosis and coronary artery disease, and reducing formation of plaque on vascular walls and methods of using same. More particularly, the present invention relates to dietary supplements comprised of gallic acid, or a derivative thereof, in combination with limonene, or a derivative thereof, formulated so as to effectively reduce plaque formation, reversing plaque deposition and degenerative changes in the arterial walls, and/or removal of existing plaques from the vascular walls of animals, preferably humans. The dietary supplements may be formulated “neat” (e.g., without additives) or with additives such as pharmaceutical carriers, diluents, buffers, adjuvants, excipients, surfactants, and stabilizers.

Abstract: Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.

Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis.

Abstract: A composition is prepared by extracting phytochemicals from plant matter and is administered to provide treatment for cardiovascular medical conditions, such as: excessive bloodstream cholesterol, the risk of heart disease, abnormal blood lipid profiles, and abnormal vascular effects. This composition is enriched preferably with two or more fractions of plant matter, namely: isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids. The isoflavones are selected from a group including malonyl, acetyl, glucoside and aglycone. Soy is the preferred source of these chemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The composition is a dietary supplement in a concentrated form, preferably in an easy to consume form, for treatment of various cardiovascular conditions and various other related disorders.

Abstract: Pomegranate extracts and methods of use thereof are provided. Particularly, an antioxidative composition comprising an extract from pomegranate is provided. A method of reducing lipid peroxidation, aggregation or retention, HDL oxidation in a sample and a method of alleviating atherosclerosis in a patient are also provided.

Abstract: Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.

Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for decreasing platelet adhesiveness.

Abstract: A method for mediating the activity of PPAR-&ggr; receptor comprising contacting said PPAR-&ggr; receptor with a compound of formula I defined herein. Also disclosed is the treatment of a patient suffering from a physiological disorder capable of being modulated by a compound of formula I having PPAR-&ggr; ligand binding activity, comprising administering to the patient a pharmaceutically acceptable amount of the compound, or a pharmaceutically acceptable salt thereof.

Abstract: Pomegranate extracts and methods of use thereof are provided. Particularly, an antioxidative composition comprising an extract from pomegranate is provided. A method of reducing lipid peroxidation, aggregation or retention, HDL oxidation in a sample and a method of alleviating atherosclerosis in a patient are also provided.

Abstract: The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.

Abstract: Pomegranate extracts and methods of use thereof are provided. Particularly, an antioxidative composition comprising an extract from pomegranate is provided. A method of reducing lipid peroxidation, aggregation or retention, HDL oxidation in a sample and a method of alleviating atherosclerosis in a patient are also provided.

Abstract: A method for preventing or treating high serum levels of cholesterol and lipids in a mammal, said method comprising orally administering an effective amount of natural lycopene to prevent or treat high serum levels of cholesterol or lipid to a mammal in need of such treatment. Also disclosed is an oral pharmaceutical composition in unit dosage form for oral administration for the prevention or treatment of high serum levels of cholesterol and/or lipids in a mammal, said composition comprising an effective amount of natural lycopene to prevent or treat high serum levels of cholesterol or lipid in a mammal and in a sufficient amount to achieve a level of serum cholesterol of less than 200 mg per deciliter over the course of treatment, and a pharmaceutically acceptable carrier therefor.

Abstract: Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.

Abstract: The present invention relates to the use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arteriosclerosis or for anticoagulative treatment.

Abstract: A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.

Abstract: A method of-treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.

Abstract: The invention concerns powder compositions of stabilised unilamellar liposomes, comprising at least an external lipid phase and a internal aqueous polar nucleus gelled at room temperature, the method for preparing them and their applications as nutritional additives and in pharmaceutical compositions to be orally administered (with action against lipemia). Said compositions essentially consist of unilamellar liposomes comprising an external lipid phase consisting of class 4 lipids (phospholipids) and an internal aqueous nucleus consisting essentially of a mixture M of at least two different non-polymerisable gelling agents (G1 and G2) whereof the gel-sol phase transition point is not less than 37° C.

Abstract: This invention discloses a kind of pine needle extract. The extract can be used to treat the following diseases: hypertension, coronary heart disease, angina pectoris, arrhythmia, diabetes, hyperlipemia, high blood viscosity, high blood aggregation, scleratheroma, cerebral infarction, brain scleratheroma, senile dementia, sudden deafness, etc.

Abstract: An oil or fat composition comprising an oil or fat comprising 15 wt. % or more of a diacylglycerol and 1.2 to 20 wt. % of phytosterol, dissolved or dispersed in the fat and oil is provided here, which can be used in the same way as usual oil and fat in daily life to reduce a hemal cholesterol value of a person having a high value of cholesterol and to raise no problem in appearance, taste, heating cooking and the like in comparison with usual edible oil and fat.

Abstract: The invention provides the use of dipyridoxyl or aminopolycarboxylic acid based chelating agents, metal chelates and salts thereof, in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of atherosclerosis and related conditions in the human or non-human animal body.

Abstract: The present invention provides a method for treating a demyelinating disease in a subject which includes administering to the subject a therapeutically effective amount of a high affinity neuromodulatory Na,K-ATPase so as to treat the demyelinating disease.

Abstract: In accordance with the present invention, there are provided therapeutically effective compounds comprising an amphipathic carboxylate of the formula R—COOH, or a salt or an ester or amide of such compound, where R designates a saturated or unsaturated alkyl chain of 10-24 carbon atoms, one or more of which may be replaced by heteroatoms, where one or more of said carbon or heteroatom chain members optionally forms part of a ring, and where said chain is optionally substituted by a hydrocarbyl radical, heterocyclyl radical, lower alkoxy, hydroxyl-substituted lower alkyl, hydroxyl, carboxyl, halogen, phenyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted phenyl, C3-C7 cycloalkyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted C3-C7 cycloalkyl wherein said amphipathic carboxylate is capable of being endogenously converted to its respective coenzyme A thioester.

Abstract: The invention concerns new guanidine derivatives of formula (I), methods of preparing them and their use in drugs containing such compounds.

Abstract: A method is provided for suppressing atherogenesis in which a cholesterol 20-hydroperoxide is administered, which is preferably one or both of the novel compounds: 20(R)-hydroperoxy-25-hydrocholesterol and 29(S)-hydroperoxy-25-hydrocholesterol 20(R)-hydroperoxy-25 hydrocholesterol and 20(S)-hydroperoxy-25-hydrocholesterol are administered. The compositions 20(R)-hydroperoxy-25-hydrocholesterol and 20(S)-hydroperoxy-25-hydrocholesterol are also provided.